PRN2246/SAR442168 data is likely to disappoint investors. The recent BTKi hype is related to cancer indications where Principia Biopharma has little prospect. Their buyout rumour premium isn't ...

Find out how you can get the best content on Seeking Alpha here. We are short shares of Principia Biopharma (NASDAQ: PRNB), a company whose $2 billion valuation rests on a single obscure molecule ...

SOUTH SAN FRANCISCO, Calif., May 14, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to ...

Principia’s Bruton tyrosine kinase (BTK) inhibitors add to Sanofi’s efforts to accelerate and build a portfolio of the next generation of transformative treatments for autoimmune diseases.

SOUTH SAN FRANCISCO, Calif., March 01, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq:PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies ...

SAN FRANCISCO, Oct. 29, 2012 -- SAN FRANCISCO, Oct. 29, 2012 /PRNewswire/ -- Principia Biopharma, Inc., a privately-held biopharmaceutical company focused on advancing best-in-class medicines in ...

Principia Biopharma Inc. PRNB was a big mover last session, as the company saw its shares rise more than 9% on the day. The move came on solid volume too with far more shares changing hands than ...

Sanofi’s Principia Biopharma is taking a one-two punch. Just days after one of the subsidiary's key BTK inhibitors crashed out of clinical testing, Sanofi has now disclosed it will wind down ...

March 11, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant ...

Already a Vigil Neuroscience investor, Sanofi has agreed to buy the rest of the biotech’s shares for $8 apiece, representing ...

Is Principia Biopharma Inc. (NASDAQ:PRNB) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before doing days of research on it.

PARIS and SOUTH SAN FRANCISCO, Calif., Aug. 17, 2020 /PRNewswire/ -- Sanofi and Principia Biopharma Inc. (NASDAQ: PRNB), a late-stage biopharmaceutical company focused on developing treatments for ...